Dendritic Cell Activating Scaffold in Melanoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions

Melanoma

Interventions

BIOLOGICAL

WDVAX

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

Dana-Farber Cancer Institute

OTHER

NCT01753089 - Dendritic Cell Activating Scaffold in Melanoma | Biotech Hunter | Biotech Hunter